Back to search
Medium-chain Acyl-CoA Dehydrogenase Deficiency
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Medium-chain Acyl-CoA Dehydrogenase Deficiency trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Medium-chain Acyl-CoA Dehydrogenase Deficiency trials you may qualify forThe aim of this project is to investigate the physiological effects of intake of long-chain fatty acids (LCFA) and medium-chain fatty acids (MCFA) in patients w…
This is a medical research study to test a medication in patients 4 years of age and older with a disease called medium-chain acyl-CoA dehydrogenase deficiency…
This is a medical research study to test a medication in patients 4 years of age and older with a disease called medium-chain acyl-CoA dehydrogenase deficiency…
Ammonia is a waste product of protein and amino acid catabolism and is also a potent neurotoxin. High blood ammonia levels on the brain can manifest as cytotoxi…
This is a medical research study to test a medication in adult patients with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD). The medica…
Expanded access may be provided for qualified patients who have limited treatment options and are not eligible for a clinical trial.
The main goal of this study is to evaluate the effects of triheptanoin versus Medium-chain Triglycerides (MCT) on frequency of Major Clinical Events (MCEs).